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The synthesis of adiponectin, an adipokine with
ill-defined functions in animals fed a normal diet, is
enhanced by the osteoblast-derived hormone osteo-
calcin. Here we show that adiponectin signals back
in osteoblasts to hamper their proliferation and favor
their apoptosis, altogether decreasing bone mass
and circulating osteocalcin levels. Adiponectin fulfills
these functions, independently of its known recep-
tors and signaling pathways, by decreasing FoxO1
activity in a PI3-kinase-dependent manner. Over
time, however, these local effects are masked
because adiponectin signals in neurons of the locus
coeruleus, also through FoxO1, to decrease the
sympathetic tone, thereby increasing bone mass
and decreasing energy expenditure. This study
reveals that adiponectin has the unusual ability to
regulate the same function in two opposite manners
depending on where it acts and that it opposes,
partially, leptin’s influence on the sympathetic
nervous system. It also proposes that adiponectin
regulation of bone mass occurs through a PI3-
kinase-FoxO1 pathway.
INTRODUCTION
The existence of a reciprocal regulation between bone and
energy metabolisms is supported by a growing number of evi-
dence (Karsenty and Oury, 2012). Two hormones, osteocalcin
and leptin, are the overarching determinants of this process.
Osteocalcin, a bone-derived hormone, regulates energy meta-
bolism, in part, by promoting insulin secretion by pancreatic b
cells (Lee et al., 2007). In a feed-forward loop, insulin signals
back in osteoblasts to enhance osteocalcin activity and there-
fore insulin secretion (Ferron et al., 2010). Osteocalcin also sig-
nals in adipocytes, where it favors the synthesis of the secreted
molecule adiponectin (Lee et al., 2007). That insulin signals backCto osteoblasts and influences osteocalcin activity raises the
prospect that adiponectin might do the same.
The adipocyte-derived hormone leptin prevents bone mass
accrual in all species in which this was tested (Ducy et al.,
2000; Elefteriou et al., 2004; Henry et al., 1999; Vaira et al.,
2012). In the mouse, a mediator of leptin regulation of bone
mass accrual is the sympathetic nervous system (Takeda
et al., 2002). The development of high bone mass in the face of
hypogonadism, as seen in the absence of leptin signaling, is a
unique situation that underscores the importance of the leptin-
dependent sympathetic regulation of bone mass accrual. It
also raises the prospect that, as it is the case for its regulation
of appetite (Erickson et al., 1996), leptin stimulation of the sym-
pathetic nervous system may be opposed by another secreted
molecule. Such a molecule has not been identified yet.
Adiponectin, another adipocyte-derived secreted molecule,
is best known for its insulin-sensitizing ability in animals fed a
high-fat diet (Kadowaki et al., 2006;Maeda et al., 2002), although
its absence does not appear to overtly alter insulin sensitivity in
animals fed a normal diet (Ma et al., 2002; Maeda et al., 2002).
It seems unlikely that adiponectin would only function in animals
fed a high-fat diet since when it appeared during evolution this
diet did not exist, nor were there any reasons to anticipate its
eventual appearance. Moreover, even in present days, most
animals never encounter this situation in the wild. A plausible
explanation for this apparent lack of metabolic function in
animals fed a normal diet is that adiponectin affects a biological
process other than energy metabolism (Denzel et al., 2010;
Sharma et al., 2008; Takemura et al., 2007). The appearance of
adiponectin during evolution with bones (Figure 1A) and its
regulation by osteocalcin are two reasons to suspect that bone
could be a target tissue of this hormone. This hypothesis began
to be tested in vivo through gain- and loss-of-function ex-
periments. Some of these studies indicated that adiponectin
affects bone mass; however, they did not provide molecular or
cellular mechanisms for its action, nor did they study whether
adiponectin affects osteocalcin (Oshima et al., 2005; Shinoda
et al., 2006).
Adiponectin biology is further complicated by the fact that
several receptors and more than one signaling pathway have
been associated with this hormone. Expression cloningell Metabolism 17, 901–915, June 4, 2013 ª2013 Elsevier Inc. 901
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and AdipoR2, as receptors for adiponectin. Those receptors
were subsequently shown to transduce adiponectin signal either
in an AMP kinase (AMPK)-dependent or in an AMPK-indepen-
dent but ceramide-dependent manner (Yamauchi et al., 2003;
Holland et al., 2011). Adiponectin also binds to T-cadherin, a
cell-surface molecule that lacks, however, any intracellular moi-
ety (Hug et al., 2004). Collectively, these observations suggest
that, as it is the case for its function(s), the signaling mechanisms
used by adiponectin may not be fully elucidated.
Testing of whether bone is a target tissue of adiponectin
revealed that this hormone exerts two opposite influences on
this tissue. First, it signals in osteoblasts, prevents their prolifer-
ation, and increases their apoptosis in a PI3-kinase-FoxO1-
dependent manner, and as a result it decreases bone formation,
bone mass, and circulating osteocalcin levels. Yet these func-
tions are rapidly masked because adiponectin also signals in
the brain, through FoxO1, to inhibit the activity of the sympa-
thetic nervous system, thereby increasing bone formation and
bone mass and decreasing energy expenditure and blood pres-
sure. These results identify target cells and functions and pro-
pose a signaling mechanism for adiponectin in animals fed a
normal diet. They also indicate that adiponectin opposes,
partially, leptin’s influence on the sympathetic nervous system
and the physiological functions that it regulates.
RESULTS
Adiponectin Inhibits Bone Mass Accrual in Young Mice
Proteins with significant homology to adiponectin are found
only in bony vertebrates (Figure 1A). This could mean that
adiponectin is expressed in, or signals in, bone cells. To test
the first possibility, we measured Adiponectin expression in
adipocytes and bone cells obtained from wild-type (WT) and
Adiponectin/ mice. Adiponectin expression was 10,000-fold
higher in WT adipocytes than in bone cells; moreover, there
was no difference in Adiponectin expression between WT and
Adiponectin/ osteoblasts and osteoclasts (Figure 1B). Like-
wise, quantitative PCR and in situ hybridization analyses failed
to detect Adiponectin expression in osteocytes (Figures S1E–
S1G available online). Thus, the appearance of adiponectin
with bone during evolution cannot be explained by its expres-
sion in bone cells.
To address the second possibility, we measured the expres-
sion of multiple genes in cell populations enriched with calvarial
osteoblasts or in osteoclasts derived in vitro from bone-marrow-
derived cells. These cells were then treated with recombinant
mouse full-length adiponectin for 4 hr. Among all the genes
tested, only Rankl, a gene expressed in osteoblasts and encod-
ing an osteoclast differentiation factor (Lacey et al., 1998), saw
its expression increased more than 10-fold after stimulation
by even low amounts of adiponectin or its globular domain (Fig-
ures 1C, S1A, and S1H). The same stimulation of Rankl expres-
sion was observed when enriched populations of osteoblasts
derived from bone marrow cells treated with adiponectin for 2,
4, and 8 hr were used (McCulloch et al., 1991) (Figure S1H).
These results identifying the osteoblast and Rankl as an adipo-
nectin target cell and gene implied that this hormone should
inhibit bone mass accrual by favoring bone resorption. This902 Cell Metabolism 17, 901–915, June 4, 2013 ª2013 Elsevier Inc.hypothesis was tested through the study of Adiponectin/
mice fed a normal diet. Since Adiponectin/ mice of either
gender displayed the same bone mass abnormality at a later
age (Figures 3A and S2A), we used only male mice for the rest
of this study.
At 6 and, to a lesser extent, 12 weeks of age, Adiponectin/
mice fed a normal or high-fat diet showed the expected high-
bone-mass phenotype affecting the axial and appendicular
skeleton and the trabecular and cortical bones (Figures 1D, 1E,
S1B, and S2I). Consequently, Adiponectin/ bones had better
biomechanical properties than did WT ones (Figure 1F). Sur-
prisingly, however, this high bone mass was not caused by a
decrease in bone resorption since Rankl expression was
mildly affected and the osteoclast number was not significantly
changed in Adiponectin/ bones. What explained, instead,
this high-bone-mass phenotype in Adiponectin/ mice was a
massive increase in the osteoblast number (Figures 1D and
1G) that resulted in an increase in the rate of bone formation
and in circulating levels of total and undercarboxylated osteo-
calcin (Figure 1H). This high-bone-mass phenotype could not
be explained by abnormal insulin sensitivity since insulin toler-
ance tests were normal throughout life in Adiponectin/ mice
fed a normal diet (Figure S1C). In contrast, 12-week-old
Adiponectin/ mice fed a normal diet showed a significant
decrease in insulin secretion as measured by a glucose-
stimulated insulin secretion (GSIS) test and an intolerance
to glucose as determined by a glucose tolerance test (GTT) (Fig-
ures 1L and 1M). A mechanism explaining these abnormalities
was later identified (see below).
We also analyzed transgenic mice harboring a 5-fold increase
in adiponectin circulating levels (pLiv-Adiponectin) (Figure 1I).
Mirroring what was seen in Adiponectin/ mice, 12-week-old
pLiv-Adiponectin mice showed a low-bone-mass phenotype
due to a significant decrease in osteoblast number (Figure 1J).
Consequently, total and undercarboxylated circulating osteocal-
cin levels were significantly decreased in these mice compared
to WT littermates (Figure 1K). Hence, both loss- and gain-of-
function models identify adiponectin as a regulator of osteoblast
number, bone formation, and circulating osteocalcin levels.
Adiponectin Inhibits Proliferation and Favors Apoptosis
of Osteoblasts
Since it is the basis of the bone phenotypes of Adiponectin/
and pLiv-Adiponectin mice, we investigated how adiponectin
regulates the osteoblast number. While expression of osteoblast
differentiation markers such as Runx2 and Osterix was unaf-
fected in Adiponectin/ bones and in adiponectin-treated oste-
oblasts (Figures 1C and S1D), three cellular abnormalities could
explain the elevated osteoblast number of Adiponectin/mice.
First, proliferation of osteoblast progenitor cells, as mea-
sured by BrdU incorporation and CyclinD1 accumulation, was
increased in Adiponectin/ bones, and adiponectin treatment
of mouse osteoblast progenitor cells decreased their prolifera-
tion and CyclinD1 accumulation (Figures 2A–2D). Second, there
was a decrease in osteoblasts apoptosis in Adiponectin/
bones as measured by a TUNEL assay and by the number of
Annexin-V-positive osteoblasts (Figures 2E and 2G). Conversely,
adiponectin treatment of osteoblast progenitor cells increased
the number of TUNEL-positive cells and the production of
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Figure 1. Adiponectin Regulation of Rankl and Bone Mass
(A) Conservation of adiponectin, AdipoR1, AdipoR2, and T-cadherin sequences among vertebrate and invertebrate species.
(B) Relative expression of Adiponectin in WT and Adiponectin/ adipocyte, osteoblast, and osteoclast populations.
(C) Adiponectin regulation of gene expression analyzed by quantitative PCR. Primary osteoblast or osteoclast cell populations were treated with indicated
concentrations of adiponectin for 4 hr.
(D) Bone histomorophometric analysis of 6- and 12-week-old WT (n > 10) or Adiponectin/ (n > 10) mice. BV/TV, bone volume over tissue volume; Ob.N/T.Ar,
number of osteoblasts per trabecular area; BFR, bone formation rate; OcS/BS, osteoclast surface per bone surface; ES/BS, eroded surface per bone surface.
(E) mCT analysis of 6-week-old WT (n = 5) or Adiponectin/ mice (n = 5). Cort.Th, cortical thickness; Conn-Den, connective density; Tb.N, trabecular number.
(F and G) Three-point bending test and Rankl expression in 6-week-old Adiponectin/ bones.
(H) Total and uncarboxylated osteocalcin serum levels in 6-week-old Adiponectin/ mice.
(I) Adiponectin serum levels in 12-week-old pLiv-Adiponectin (pLiv-Apn) mice.
(J) Bone histomorphometric analysis of 12-week-old WT (n = 10) and pLiv-Adiponectin mice (n = 8).
(K) Total and uncarboxylated osteocalcin serum levels in 12-week-old pLiv-Adiponectin mice.
(L and M) GTT and GSIS test in 12-week-old Adiponectin/ mice.
For all panels, results are given as means ± SEM. *p < 0.05 by ANOVA and/or Student’s t test. NS, not significant; N.D, not determined. See also Figure S1.
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Adiponectin Functions in Animals Fed a Normal Dietcleaved caspase-3 by osteoblasts (Figures 2F and 2H). Third,
there was a decrease in oxidative stress defined by the
production of malondialdehyde and 4-hydroxynonenal and
accumulation of reactive oxygen species in Adiponectin/
osteoblasts; this may also trigger apoptosis (Finkel and
Holbrook, 2000) (Figures 2I and 2J). That none of these abnor-
malities were observed when hepatocytes and myoblasts were
treated with adiponectin suggests that the influence of this
hormone on osteoblasts is, to an extent, specific to this cell
type (Figures 2B and 2F). In summary, by signaling in osteo-Cblasts, adiponectin inhibits bone formation and decreases
circulating osteocalcin levels because it decreases proliferation
and favors apoptosis of osteoblasts.
Adiponectin Favors Bone Mass Accrual in Older Mice
A singular feature of the high-bone-mass phenotype displayed
by Adiponectin/mice is that it peaked at an early age. Indeed,
the 2-fold increase in osteoblast number seen in 6-week-old
mutant mice had largely vanished once these mice reached
3 months of age. This dynamic influence of adiponectin onell Metabolism 17, 901–915, June 4, 2013 ª2013 Elsevier Inc. 903
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Figure 2. Adiponectin Regulates Osteoblast Proliferation and Apoptosis
(A and B) BrdU incorporation in 10-day-old Adiponectin/ bones or WT osteoblasts, myoblasts, or hepatocytes treated with vehicle or adiponectin for 24 hr.
(C and D) Cyclins accumulation in 6-week-old Adiponectin/ bones and WT osteoblasts treated with vehicle or adiponectin for 24 hr.
(E and F) TUNEL assay in 10-day-old Adiponectin/ bones and WT osteoblasts, myoblasts, or hepatocytes treated with vehicle or adiponectin for 24 hr.
(G) Annexin-V-positive 6-week-old Adiponectin/ osteoblasts.
(H) Cleaved caspase-3 accumulation in WT osteoblasts treated with vehicle, adiponectin, or H2O2 (100 mM) for 24 hr.
(I and J) Quantification of malondialdehyde, 4-hydroxynonenal, and reactive oxygen species (ROS) in 6-week-old Adiponectin/ osteoblasts.
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Adiponectin Functions in Animals Fed a Normal Dietbone mass accrual led us to analyze Adiponectin/ mice at
multiple time points.
Bone formation, bone resorption parameters, and bone mass
were normal, if not slightly decreased, in 6-month-old male and
female Adiponectin/mice, and evenmore striking was the fact
that 9-month-old Adiponectin/ mice demonstrated a severe904 Cell Metabolism 17, 901–915, June 4, 2013 ª2013 Elsevier Inc.low-bone-mass phenotype affecting all skeletal elements tested
(Figures 3A, S2A, and S2B). This was due to the conjunction of a
decrease in the number and proliferation ability of osteoblasts
(Figures 3A–3C) and an increase in bone resorption parameters
such as osteoclast surface, CTx serum levels, and Rankl ex-
pression (Figures 3A, 3D, and 3E). In other words, the bone
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Adiponectin Functions in Animals Fed a Normal Dietphenotype of older Adiponectin/ mice and the cellular abnor-
malities explaining it were exactly opposite to those seen in
younger ones.
Two other physiological functions were also affected in 9-
month-old Adiponectin/ mice fed a normal diet. First, there
was a marked increase in energy expenditure during both dark
and light cycles (Figure 3F). As a result, fat-pad weight did not
increase overtime in Adiponectin/ as it did in WT mice (Fig-
ure 3G). Paradoxically, given this massive increase in energy
expenditure, appetite was not increased and in fact was slightly
decreased in older Adiponectin/ mice. This explained why
the body weight of 9-month-old Adiponectin/ mice was sig-
nificantly lower than the one of WT littermates (Figures 3H and
S2E). Expression of genes affecting appetite, such Mc4r, Npy,
and Cart, was similar between Adiponectin/ and WT mice
(Figure S2D). Second, blood pressure and heart rate were sig-
nificantly increased in Adiponectin/ mice compared to WT
littermates (Figures 3I and 3J).
Adiponectin Inhibits the Activity of the Sympathetic
Nervous System
Two observations suggested that the phenotype observed in
older Adiponectin/ mice could be due to an increase in the
sympathetic tone. The first one is that adiponectin crosses
the blood brain barrier (Figure 3K) (Kusminski et al., 2007; Qi
et al., 2004). To determine whether adiponectin accumulates
in the locus coeruleus, where the sympathetic nervous system
originates from (Rush and Geffen, 1980), we delivered it in
Adiponectin/ mice and analyzed where it binds. In the condi-
tions of this experiment, adiponectin bound to neurons express-
ing DBH, a specific marker of neurons of the locus coeruleus
(Thomas et al., 1995). That an excess of nonlabeled adiponectin
abolished biotinylated-adiponectin binding to DBH-expressing
neuronswhereas biotinylated-GST did not verified the specificity
of this binding (Figure 3L). A second reason to test whether
adiponectin regulates the sympathetic tone is that the sympa-
thetic nervous system is known to inhibit bone formation, to
favor bone resorption, to increase energy expenditure and
blood pressure, to promote liver gluconeogenesis, and to inhibit
insulin secretion (Elefteriou et al., 2005; Nonogaki, 2000; Takeda
et al., 2002; Tentolouris et al., 2006).
As hypothesized, whether we measured norepinephrine
content in the brain, Ucp1 expression in brown fat, or urinary
epinephrine elimination, there was, throughout life, a nearly
2-fold increase in the sympathetic tone in Adiponectin/ mice
compared to WT littermates fed a normal or a high-fat diet (Fig-
ures 3M–3O and S2H). As a result, Ucp1 expression was higher
in white adipose tissue of 9-month-old Adiponectin/ mice,
reflecting a ‘‘beiging’’ of white fat (Figure 3P) (Wu et al., 2012).
Conversely, Ucp1 expression in brown fat was lower in pLiv-
Adiponectin than in WT mice (Figure 3N). Since the sympathetic
tone enhances bone resorption by increasing Rankl expression
(Elefteriou et al., 2005), we speculate that the high sympathetic
activity seen in Adiponectin/ mice antagonizes the conse-
quence on Rankl expression of the absence of adiponectin
signaling in osteoblasts. This may explain the overall normal
bone resorption noted in young Adiponectin/ mice.
If the increase in sympathetic activity explains the low bone
mass of older Adiponectin/ mice, normalizing it should resultCin a high-bone-mass phenotype because of the absence of
adiponectin signaling in osteoblasts. This assumption was
tested by removal of one allele of Dopamine b-hydroxylase
(Dbh), the gene encoding the initial enzyme in catecholamine
biosynthesis, from Adiponectin/ mice (Thomas et al., 1995).
That Ucp1 expression in brown fat, norepinephrine content
in the brain, and urinary epinephrine elimination were similar in
Adiponectin/;Dbh+/ and control littermates verified that the
sympathetic activity was normalized in the compound mutant
mice (Figures S3A–S3C). Nine-month-old Adiponectin/;
Dbh+/ mice presented an increase in bone mass secondary to
an increase in osteoblast numbers and bone formation rate
(Figures 4A–4C and S3E). At the same time, energy expenditure
and fat-pad and body weights were normal in these compound
mutant mice (Figures 4E-F and S3D). That normalization of
sympathetic tone in 12-week-old Adiponectin/ mice also
normalized GTTs and GSIS tests indicates that the decrease in
insulin secretion seen in the absence of adiponectin is secondary
to the increase in sympathetic activity (Figures S3F and S3G).
To determine whether it is by signaling in osteoblasts that
the sympathetic nervous system antagonizes the local effect of
adiponectin, we generated Adiponectin/ mice lacking one
copy of Adrb2, the adrenergic receptor mediating sympathetic
signaling in osteoblasts (Takeda et al., 2002), in these cells
only. Three-month-old Adiponectin/;Adrb2osb
+/ mice had
significantly higher bone mass than did Adiponectin/ mice
(Figure 4G). Taken together, these experiments support the
notion that adiponectin favors bonemass accrual and decreases
energy expenditure by inhibiting sympathetic signaling in
osteoblasts. This mechanism of action eventually masks the
consequence of the absence of signaling of this hormone on
osteoblasts.
Adiponectin Antagonizes Leptin Regulation
of the Sympathetic Tone
Since adiponectin and leptin exert opposite influences on sym-
pathetic activity, we wondered what might be the consequences
of removing Adiponectin from ob/ob mice (Adiponectin/;
ob/ob). Although not normalized, Ucp1 expression and urinary
epinephrine levels were increased 2-fold in 6- and 10-week-old
Adiponectin/;ob/ob compared to ob/ob mice (Figures 4H,
S3I, and S3L). As a result, energy expenditure was significantly
higher in Adiponectin/;ob/ob than in ob/ob mice at both 6
and 10 weeks of age (Figures 4I and S3M), and these mutant
mice gained less weight and had lighter fat-pad weight than
did ob/ob mice for as long as this was tested (Figures 4J, S3H,
and S3K). Moreover, blood pressure and heart rate were normal
in 6-week-old Adiponectin/;ob/ob mice (Figures 4K and 4L).
Since the correction of the low sympathetic tone observed in
ob/ob mice by Adiponectin deletion is only partial, the glucose
metabolism abnormalities of ob/ob mice at 10 weeks of age
remained unaffected (Figure S3J). These results indicate that
adiponectin antagonizes, partially, the functions of leptin that
are mediated by the sympathetic nervous system. Ten-week-
old Adiponectin/;ob/ob mice also exhibited a lower bone
mass in both axial and peripheral bones compared to ob/ob
mice, a result consistent with the fact that adiponectin and
leptin exert an opposite influence on the sympathetic tone (Fig-
ures 4M and 4N).ell Metabolism 17, 901–915, June 4, 2013 ª2013 Elsevier Inc. 905
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Adiponectin Functions in Animals Fed a Normal DietAdiponectin Does Not Use Known Signaling Pathways
in Osteoblasts
To identify molecular mechanisms used by adiponectin to
mediate its functions in animals fed a normal diet, we focused
on osteoblasts, a cell type that can be cultured, and first asked
whether any of its known receptors were involved.
AdipoR1 was expressed at similar levels in osteoblasts
and skeletal muscle, whereas expression of AdipoR2 and
T-cadherin was 10-fold lower in osteoblasts than in tissues
in which they are abundantly expressed (Hug et al., 2004;
Yamauchi et al., 2003) (Figures 5A–5C). We next generated
mutant mouse strains lacking AdipoR1, AdipoR2, T-cadherin,
or a combination of these genes in osteoblasts only and verified
that we had efficiently deleted the gene(s) of interest in osteo-
blasts but not in other cell types (Figures S4C, S4D, S4G, S4H,
S4K, and S4L). Unlike what was the case for Adiponectin/
mice of the same age and maintained on the same genetic
background, 12-week-old AdipoR1osb
/, AdipoR2osb
/,
T-cadherinosb
/, and AdipoR1osb
/;AdipoR2osb
/ mice dis-
played normal bone mass, osteoblast number, osteoclast num-
ber, circulating osteocalcin levels, andRankl expression (Figures
5D–5G, S4M, and S4N). Moreover, in cell culture, adiponectin
induced Rankl expression equally well in fl/fl, AdipoR1/,
AdipoR2/, AdipoR1/;AdipoR2/, and T-cadherin/ oste-
oblasts (Figure 5H).
We also studied signaling pathways reported to mediate adi-
ponectin functions. Adiponectin can induce AMP kinase
(AMPK) phosphorylation in some settings (Yamauchi et al.,
2002), yet it failed to do so in cultured osteoblasts (Figure 6A).
This was not due to a poor quality of the osteoblast preparation
since adiponectin induced Rankl expression and AICAR, the
positive control in this experiment, induced robust AMPK phos-
phorylation in these cells (Figure 6A). Adiponectin has also been
proposed to enhance ceramidase activity in some target cells
(Holland et al., 2011), but there was no significant increase in
ceramide content in bones of Adiponectin/ mice fed a normal
diet (Figure 6B). Thus, the results presented here indicate that, in
osteoblasts, adiponectin may signal through distinct signaling
pathways.
Adiponectin Dual Regulation of Bone Mass Accrual
Occurs by Decreasing FoxO1 Activity
To understand how adiponectin could regulates bone mass, we
searched for a single signaling molecule regulating all threeFigure 3. Analysis of Older Adiponectin–/– Mice
(A) Bone histomorophometric analysis of 24- and 36-week-old WT (n > 10) and A
(B and C) Cyclin expression and Cyclin D1 accumulation in 36-week-old Adipon
(D–F) Serum CTx levels, Rankl expression, and energy expenditure in 36-week-o
(G–J) Fat-pad weight, body weight, blood pressure, and heart rate of 12- and/or
(K) Adiponectin accumulation in brain. Six-week-old Adiponectin/ mice receiv
hypothalamus, brainstem, cortex, and cerebellum were then measured. ND, not
(L) Adiponectin binding to locus coeruleus (LC), visualized with anti-biotin antib
antibody (green).
(M) Norepinephrine content in the brainstem of 36-week-old Adiponectin/ mic
(N) Ucp1 expression in the brown fat of 6-, 12-, and 36-week-old Adiponectin/
(O) Urinary epinephrine elimination of 6-, 12-, and 36-week-old Adiponectin/ m
(P) Ucp1 expression in 36-week-old Adiponectin/ subcutaneous fat (sub. fat).
See also Figure S2.
Ccellular events affected by adiponectin in osteoblasts, i.e., prolif-
eration, apoptosis, and oxidative stress. The transcription
factor FoxO1 affects these three cellular events in the opposite
direction that does adiponectin (Rached et al., 2010), and five
different lines of evidence indicate that it lies downstream of
adiponectin signaling in osteoblasts.
First, adiponectin and insulin, a positive control, increases
phosphorylation of FoxO1 in osteoblasts, an event that de-
creases its transcriptional activity (Burgering and Kops, 2002)
(Figure 6C). Conversely, FoxO1 is less phosphorylated, i.e.,
more active in Adiponectin/ than in WT bones (Figure 6D).
Second, adiponectin, like insulin, decreases the quantity of
FoxO1 present in the nuclear compartment of osteoblasts
(Figure S5A). Third, adiponectin treatment of ROS17/2.8
osteoblastic cells decreases activity of a Luciferase gene driven
by an artificial promoter containing multiple FoxO1 binding
sites (Figure 6E). Fourth, expression of P16 and P19, two
FoxO1 target genes in osteoblasts (Rached et al., 2010), was
increased in Adiponectin/and decreased in pLiv-Adiponectin
bones (Figure 6F). Fifth, we generated Adiponectin/mice lack-
ing one allele of FoxO1 in osteoblasts only (Adiponectin/;
FoxO1osb
+/ mice). P16 and P19 expression was similar in the
bones of Adiponectin/;FoxO1osb
+/ and control littermates
(Adiponectin+/+;FoxO1fl/+), indicating that we had normalized
FoxO1 activity in osteoblasts through this manipulation (Fig-
ure S5B). Bone mass, bone formation rate, and osteoblast
and osteoclast numbers were all indistinguishable between con-
trols and 3-month-old Adiponectin/;FoxO1osb
+/ mice (Fig-
ures 6G). BrdU incorporation and cyclin accumulation verified
that osteoblast proliferation was decreased in Adiponectin/;
FoxO1osb
+/ compared to Adiponectin/ bones (Figures 6H
and 6I), and as a result, osteocalcin circulating levels were
normal in Adiponectin/;FoxO1osb
+/ mice (Figures S5D and
S5E). Hence, adiponectin affects osteoblast proliferation,
apoptosis, and bone formation by decreasing FoxO1 activity in
osteoblasts.
Since FoxO1 is expressed in neurons of the locus coeruleus,
we asked whether it also lies downstream of adiponectin
signaling in the brain by generating Adiponectin/mice lacking
one allele of FoxO1 only in neurons of the locus coeruleus (Fig-
ure S5F). Adiponectin/;FoxO1LC
+/ mice had normal sympa-
thetic activity (Figure S5G) and normal energy expenditure,
Ucp1 expression in brown fat, and fat-pad and body weights
(Figures 6J–6L and S5H). Bone mass, osteoblast number,diponectin/ (n > 10) mice.
ectin/ bones.
ld Adiponectin/ mice.
36-week-old Adiponectin/ mice.
ed 5 mg adiponectin peripherally per day for 7 days, and adiponectin levels in
detectable.
ody (red) together with locus coeruleus-specific marker DBH with anti-DBH
e.
and 12-week-old pLib-Adiponectin mice.
ice.
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Figure 4. Analysis of Adiponectin–/–;Dbh+/–, Adiponectin–/–;Adrb2osb
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(A) Bone histomorophometric analysis of 36-week-old Adiponectin/;Dbh+/mice. WT (n > 10), Dbh+/ (n > 10), Adiponectin/ (n > 10), and Adiponectin/;
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and Adiponectin/;Dbh+/.
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Cell Metabolism
Adiponectin Functions in Animals Fed a Normal Dietand bone formation rate were significantly higher whereas oste-
oclast number, Rankl expression, and serum CTx levels were
lower in Adiponectin/;FoxO1LC
+/ than in Adiponectin/
mice (Figures 6M–6O and S5I), indicating that FoxO1 is also
part of the adiponectin signaling pathway in neurons of the locus
coeruleus.
Adiponectin Affects FoxO1 Phosphorylation
in a PI3-Kinase-Dependent Manner in Osteoblasts
In the last set of experiments, we used information presented
above in an effort to identify a signaling cascade used by
adiponectin in osteoblasts. Adiponectin did not induce cAMP
production in osteoblasts, and inhibitors of signaling through
G-protein-coupled receptor (GPCR) did not prevent adiponec-
tin to induce Rankl expression in osteoblasts (Figures 7D, S6A,
and S6B), thus suggesting that the putative adiponectin
receptor in osteoblasts may not be a GPCR. On the other
hand, that FoxO1 phosphorylation is often regulated by PI3-
kinase-dependent events (Taniguchi et al., 2006) led us to
test whether adiponectin signaling in osteoblasts rely on
signaling events that can be elicited by PI3-kinase-dependent
mechanisms.
In support of this hypothesis, we note that adiponectin, like
insulin, could increase PI3 kinase activity in osteoblasts as
measured by the accumulation of phosphatidylinositol 3-phos-
phate (Figure 7A) and induced phosphorylation of AKT (Fig-
ure 7B), a signaling molecule acting downstream of PI3 kinase
(Engelman, 2009). Adiponectin-dependent phosphorylation of
AKT and FoxO1 was abolished when osteoblasts were pre-
treated with LY294002, a PI3 kinase inhibitor, but not by inhibi-
tors of signaling through GPCR (Figures 7C–7E and S6B).
Furthermore, adiponectin treatment of osteoblasts induced
tyrosine phosphorylation of a protein with a molecular weight
of close to 170 kDa (Figure 7F). These results indicate that
adiponectin ability to regulate proliferation and apoptosis of
osteoblasts in a FoxO1-dependent manner is determined, at
least in part, by PI3 kinase activity.
DISCUSSION
This study, prompted by the regulation of Adiponectin expres-
sion by osteocalcin, showed that adiponectin regulates bone
mass accrual through two opposite mechanisms and counter-
acts, partially, some of leptin’s functions. It also points toward
a novel signaling mechanism for this hormone. We should
emphasize that our results do not affect in any way conclusions
reached by analysis of the function of this molecule in mice fed
a high-fat diet and in other cell types.(B–F) Serum CTx levels, Rankl expression, Cyclin D1 accumulation, energy expe
0.05 between WT and Adiponectin/; #p < 0.05 between Adiponectin/ and A
(G) Bone mass of 12-week-old Adiponectin/;Adrb2osb
+/ mice.
(H) Ucp1 expression in 6-week-old Adiponectin/;ob/ob brown fat.
(I–L) Energy expenditure, fat-pad weight, blood pressure, heart rate in 6-week-o
(M and N) Bone histomorphometric analysis of 10-week-old Adiponectin/;ob
and Adiponectin/;ob/ob (n = 7) are shown. *p < 0.05 between WT and Adip
Adiponectin/;ob/ob; #p < 0.05 between Adiponectin/ and ob/ob; ##p < 0
Adiponectin/;ob/ob and ob/ob.
See also Figure S3.
CAdiponectin Exerts Two Opposite Influences
on Bone Mass Accrual
By showing that the inactivation of Adiponectin in otherwise
unchallenged mice results in significant perturbations of their
bone mass, our results identify the regulation of bone mass
accrual by adiponectin as physiologically relevant. This regula-
tion, consistent with the appearance of adiponectin with bone
during evolution, is unusual because it relies on two mecha-
nisms, one local and one central, that antagonize each other.
On the one hand, adiponectin acts directly in osteoblasts to
prevent their proliferation and increase their apoptosis; this
is why young Adiponectin/ mice display a high bone mass
caused by an increase in bone formation parameters. Bone
may not be the only tissue affected by peripheral actions of
adiponectin in animals fed a normal diet; however, we note
that the influence that adiponectin exerts on proliferation and
apoptosis of osteoblasts was not observed in other cell types
such as myoblasts and hepatocytes. Over time, however, this
local effect is obscured by a second and more powerful mode
of action of adiponectin, its ability to decrease activity of
the sympathetic nervous system. This is why mice lacking
Adiponectin develop, as they age, a severe low-bone-mass
phenotype explained by the deleterious influence of a high
sympathetic tone on bone mass accrual that is never seen in
young mutant mice (Elefteriou et al., 2005; Takeda et al., 2002).
This latter mode of action illustrates the importance of the sym-
pathetic nervous system as a regulator of bone mass accrual
(Guntur and Rosen, 2012) and suggests that an increase of
adiponectin signaling through pharmacological means may pre-
vent age-related bone loss by decreasing the sympathetic tone.
Remarkably, the two opposite modes of action of adiponectin
target the same molecules. Through its signaling in osteoblasts,
adiponectin inhibits osteoblast proliferation and CyclinD1 accu-
mulation, and through its central signaling, it favors osteoblast
proliferation and CyclinD1 accumulation in osteoblasts. Like-
wise, adiponectin increases Rankl expression in osteoblasts,
but through its signaling in the brain and its effect on the sympa-
thetic tone, it inhibits Rankl expression. The fact that the same
hormone exerts opposite influences on the same physiological
function as adiponectin does is, to the best of our knowledge,
a rare future. The availability of a growing number of mutant
mouse strains each lacking a specific hormone will allow testing
of whether this is a more universal rule of endocrinology.
Adipocytes Secrete Two Hormones Exerting Opposite
Influence on the Same Physiological Process
Adiponectin defines with leptin a group of adipokines that exert
a significant regulation of bone mass in vivo. As a matter ofnditure, and fat-pad weight in 36-week-old Adiponectin/;Dbh+/ mice. *p <
diponectin/;Dbh+/.
ld Adiponectin/;ob/ob mice.
/ob vertebrae and femora. WT (n = 9), ob/ob (n = 8), Adiponectin/ (n = 7),
onectin/; **p < 0.05 between WT and ob/ob; ***p < 0.05 between WT and
.05 between Adiponectin/ and Adiponectin/;ob/ob; $p < 0.05 between
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Figure 5. Known Adiponectin Receptors and Signaling Pathways Do Not Mediate Adiponectin Function in Osteoblasts
(A–C) AdipoR1, AdipoR2, and T-cadherin expression in osteoblasts, muscle, and liver.
(D–G) Bone histomorophometric analyses of 12-week-old AdipoR1osb
/, AdipoR2osb
/, AdipoR1osb
/;AdipoR2osb
/, or T-cadherin osb
/ mice.
(H)Rankl expression in 12-week-oldAdipoR1osb
/,AdipoR2 osb
/, T-cadherin osb
/, andAdipoR1osb
/;AdipoR2osb
/ or fl/fl osteoblasts treated with vehicle
or adiponectin.
See also Figure S4.
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Adiponectin Functions in Animals Fed a Normal Dietfact, uncovering adiponectin regulation of bone mass accrual
shows how this hormone counteracts, partially, leptin functions
that are mediated by the sympathetic nervous system.
Although we had hypothesized that hormone(s) opposing
leptin’s influence on bone mass accrual would exist, the fact
that it is also synthesized by adipocytes was unexpected.
Thus, it appears that the adipocyte is a rare if not unique910 Cell Metabolism 17, 901–915, June 4, 2013 ª2013 Elsevier Inc.example of an endocrine cell secreting two hormones exerting
exactly opposite influences on the same physiological func-
tions. Again, the fact that many mutant mouse strains are
now available to study the biology of most hormones should
allow one to test whether this aspect of adipocyte biology is
a specific feature of this cell type or whether it applies to other
endocrine cells. In any case, the results presented in this study
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Cell Metabolism
Adiponectin Functions in Animals Fed a Normal Dietunderscore the importance of adipocytes in the control of bone
mass accrual.
Mediation of Adiponectin Regulation of Bone Mass
Accrual
The identification of adiponectin as a regulator of bone mass
accrual begged the question of the nature of the signaling path-
way(s) this hormone used in osteoblasts and neurons. Because
this cell can be studied ex vivo more easily, we focused most
of our work on osteoblasts.
A first surprising result was that deletion of any of the known
receptors for adiponectin did not recapitulate the phenotype
caused by the absence of ligand, nor did it prevent adiponectin
from enhancing Rankl expression in osteoblasts. These results
could have two explanations: either adiponectin signals through
a different receptor, or it signals through the adiponectin recep-
tor in osteoblasts, a complex made of known receptors such
as AdipoR1 and a novel one. Of note, AdipoR1 and T-cahderin
are also expressed in neurons of the locus coeruleus, where their
functions will need to be investigated (Lein et al., 2007). A second
surprising result was that adiponectin signaling does not rely
on AMPK phosphorylation or ceramidase catabolism to fulfill
its functions in osteoblasts. Instead, our analyses reveal that
one event triggered by adiponectin in osteoblasts is to decrease
the activity of the transcription factor FoxO1. That removal of one
allele of FoxO1 in osteoblasts or neurons of the locus coeruleus
from Adiponectin/ mice sufficed to correct the bone pheno-
type or their high sympathetic activity and increased energy
expenditure indicated that this molecular event is also critical
for the local and central modes of action of adiponectin.
Using this information to identify an adiponectin-dependent
signaling cascade in osteoblasts, we noticed the frequent
involvement of FoxO1 downstream of PI3 kinase signaling
(Engelman, 2009; Taniguchi et al., 2006). In agreement with
this notion, adiponectin treatment of osteoblasts increases PI3
kinase activity and phosphorylates AKT in addition to FoxO1.
Moreover, adiponectin-induced AKT phosphorylation was pre-
vented by inhibition of PI3 kinase activity. Lastly, adiponectin
phosphorylates at least one membrane protein on tyrosine
residues. We are fully aware that, in absence of a bona fide
receptor, these results are only suggestive. This being acknowl-Figure 6. FoxO1 Mediates Adiponectin Functions in Osteoblasts and N
(A) Western blot analysis of phospho-AMPK in WT osteoblasts treated with vehic
(B) Ceramide contents in 6-week-old Adiponectin/ bones.
(C and D) Western blot analysis of phospho-FoxO1 in WT and 6-week-old Adipon
15 min.
(E) FoxO1 luciferase assay in ROS 17/6.2 cells treated with adiponectin for 24 hr
(F) Expression of FoxO1 target genes in 12-week-old Adiponectin/ or pLiv-Ad
(G) Bone histomorphometric analysis of 12week-oldAdiponectin/;FoxO1osb+/
(n = 6) are shown. *p < 0.05 between controls and Adiponectin/; **p < 0.05 bet
(H) BrdU incorporation in 10-day-old Adiponectin/;FoxO1osb
+/ bones.
(I) CyclinD1 accumulation in 12-week-old Adiponectin/;FoxO1osb
+/ bones.
(J) Energy expenditure of 36-week-old Adiponectin/;FoxO1LC
+/ mice.
(K) Ucp1 expression in 36-week-old Adiponectin/;FoxO1LC
+/ brown fat.
(L) Fat-pad weight of 36-week-old Adiponectin/;FoxO1LC
+/ mice.
(M) Bone histomorphometric analysis of 36-week-old Adiponectin/;FoxO1LC
+/
(n = 5) are shown. *p < 0.05 between controls and Adiponectin/; **p < 0.05 be
(N) Rankl expression in 36-week-old Adiponectin/;FoxO1LC
+/ bones.
(O) CTx levels of 36-week-old Adiponectin/;FoxO1LC
+/ mice.
See also Figure S5.
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adiponectin signaling in osteoblasts and signaling through
a receptor tyrosine kinase that deserves further study.
In summary, this work provides evidence that adiponectin has
specific functions in animals fed a normal diet. Whether the func-
tions describe here are the only ones of adiponectin remains
to be determined. These functions, however, identify adiponec-
tin as a major regulator of bone mass and energy metabolism
and, in both cases, as an antagonist of leptin. Hence, they reveal
an unanticipated complexity in the endocrine function of the
adipocytes and illustrate how tight is the central control of
bone mass and energy expenditure (Figure 7H).EXPERIMENTAL PROCEDURES
Mouse Generation
All analyses were performed with male mice, except the bone histomorpho-
metric analysis, which was performed in 24-week-old Adiponectin/ mice
that included both males and females. Adiponectin/, AdipoR1fl/fl, Adi-
poR2fl/fl, and T-cadherinfl/fl mice were generated using 129/Sv embryonic
stem cells. The estimated percentage of each genetic background was based
on the number of backcrossing with C57BL/6J WT, a1(I) collagen-cre, or Dbh-
cremice. Chimericmice harboring amutant allele ofAdiponectinwere crossed
with C57BL/6J WT, and Adiponectin+/ progenies (estimated as C57BL/
6J:129/Sv; 50%:50%) were backcrossed with C57BL/6J WT to obtain F2
generation Adiponectin+/ mice (C57BL/6J:129/Sv; 75%:25%). Analyses
were performedwithAdiponectin/ andWT littermatemice obtained by inter-
crossing between F2-generation Adiponectin+/ mice. The pLiv-Adiponectin
construct was obtained by insertion of full-length mouse Adiponectin cDNA
into pLiv-7 plasmid (Fan et al., 1994). Transgenic mice were generated by
injection of the pLiv-Adiponectin construct into 129/Sv embryos. pLiv-
Adiponectin founder mice were crossed with C57BL/6J WT mice, and F1
generation pLiv-Adiponectin mice (C57BL/6J:129/Sv; 50%:50%) were
crossed with C57BL/6J WT to obtain pLiv-Adiponectin and WT littermates
(C57BL/6J:129/Sv; 75%:25%) for analyses. Chimeric mice harboring amutant
allele of AdipoR1, AdipoR2, or T-cahderin (Figures S4A, S4E, and S4I) were
crossed with C57BL/6J WT, AdipoR1fl/+, AdipoR2fl/+, and T-cadherinfl/+
mice (C57BL/6J: 129/Sv; 50%:50%) and were then crossed with C57BL/6J
a1(I) collagen-cre mice to obtain the F2 generation (C57BL/6J:129/Sv;
75%:25%). Analyses were performed with AdipoR1osb
/ and littermate
AdipoR1fl/fl mice; AdipoR2osb
/ and littermate AdipoR2fl/fl mice; and
T-cadherinosb
/ and littermate T-cadherinfl/fl mice obtained from crosses
between F2-generation AdipoR1osb
+/ and AdipoR1fl/+, AdipoR2osb
+/ and
AdipoR2fl/+, and T-cadherinosb
+/ and T-cadherin fl/+ mice. Analyses
of AdipoR1osb
/;AdipoR2osb
/ were performed with AdipoR1osb
/;eurons
le, 15 mg/ml adiponectin, or AICAR (0.5 mM) for 5 or 30 min.
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Figure 7. Adiponectin Signaling in Osteoblasts
(A) Accumulation of phosphatidylinositol 3-phosphate in osteoblasts treated with vehicle, adiponectin, or insulin (10 nM) in the presence PI3 kinase inhibitor of
LY294002 (10 mM) for 5 min.
(B) Western blot analysis of phospho-AKT in osteoblasts treated with vehicle, adiponectin, insulin (10 nM), or PTH (10 nM) for 5 min.
(C) Western blot analysis of phospho-AKT and phospho-FoxO1 in the presence of LY294002 (10 mM) for 5 min (P-AKT) and 15 min (P-FoxO1).
(D and E) Rankl induction and phosphorylation of AKT by adiponectin in the presence of Gs inhibitor (NF449), Gi inhibitor (NF023), Gbg inhibitor (Gallein), or PLC
inhibitor (ET-18-OCH3).
(F) Western blot analysis of phospho-tyrosine in osteoblasts treated with vehicle, adiponectin, or PTH (10 nM) for 2 min. Arrowhead, the phosphorylated band
around 170 kDa.
(G) Evolution of the bone phenotype of Adiponectin/ mice overtime.
(H) Schematic representation of the diverse functions exerted by adiponectin in mice fed a normal diet and of its two sites of action.
See also Figure S6.
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Adiponectin Functions in Animals Fed a Normal DietAdipoR2osb
/ and littermate AdipoR1fl/fl;AdipoR2fl/fl obtained by inter-
crosses between F2-generation AdipoR1osb
+/;AdipoR2osb
+/ mice (C57BL/
6J:129/Sv; 75%:25%). Dbh+/ mice were previously reported (Thomas et al.,
1995). Analyses of Adiponectin/;Dbh+/ mice were performed with litter-
mate WT, Dbh+/, and Adiponectin/ mice as controls generated by inter-
crosses between Adiponectin+/;Dbh+/ mice (C57BL/6J:129/Sv; 87.5%:
12.5%). ob/ob mice were obtained from Jackson Laboratory. Analyses
of Adiponectin/;ob/ob mice were performed with littermate WT,
Adiponectin/, and ob/ob mice as controls generated by intercrosses
between Adiponectin+/; ob/+ mice (C57BL/6J:129/Sv; 93.75%:6.25%).
FoxO1osb+/ mice were previously reported (Rached et al., 2010). Analyses
of Adiponectin/;FoxO1osb
+/mice were performed with littermate FoxO1fl/+
(controls in figures) and Adiponectin/;FoxO1fl/+ (Adiponectin/ in the fig-
ures and the main text) (C57BL/6J:129/Sv; 93.75%:6.25%) as controls.
Analysis of FoxO1osb+/mice was performed with FoxO1fl/+ littermates as
controls (Pure C57BL/6J). FoxO1LC
+/ mice were generated by crossing of
FoxO1fl/+ mice with Dbh-Cre transgenic mice (Kobayashi et al., 2004).
Analyses of Adiponectin/;FoxO1LC
+/ mice were performed with FoxO1fl/+
littermates and FoxO1LC
+/ and Adiponectin/;FoxO1fl/+ (presented as
Adiponectin/ in the figures and the main text) as controls. Normal diet and
high-fat diet were obtained from LabDiet (calories provided by protein, 24%;
fat, 13%; carbohydrates, 62%) and Research Diets (calories provided by
protein, 16%; fat, 58%; carbohydrate, 25%), respectively. All procedures
involving animals were approved byCUMC IACUC and conform to the relevant
regulatory standards.
Binding Assay
Adiponectin/ mice were implanted subcutaneously with 14 day osmotic
pump (Alzet) filled with a solution of recombinant full-length adiponectin or
vehicle (5 mg/day). After 7 days of infusion, blood vessels were injected with
PBS for extensive wash in order to remove remaining blood, and brain
regions were dissected. Tissues were homogenized in ice-cold PBS, and
soluble fractions were used to measure adiponectin. For the binding assay,
Adiponectin/ brains were snap frozen in liquid nitrogen, and 20-mm-thick
sections were prepared and desiccated overnight at 4C under vacuum. On
the following day, sections were rehydrated in ice-cold binding buffer
(50 mM Tris-HCl [pH 7.4], 10 mM MgCl2, 0.1 mM EDTA, and 0.1% BSA)
for 15 min and incubated for 1 hr at room temperature in the presence of
biotinylated adiponectin (2 mg/ml) or biotynylated GST (2 mg/ml) and in the
presence of 50-fold excess of nonbiotinylated adiponectin (100 mg/ml) or
nonbiotinylated GST (100 mg/ml). After being washed in harvesting buffer
(50 mM Tris-HCl [pH 7.4]), samples were fixed in 4% paraformaldehyde
for 15 min, washed in PBS, and incubated with goat anti-biotin antibody
(1:1000, Vector laboratories) and anti-DBH antibody (1:4000, Abcam) over-
night at 4C. The signal was visualized by incubation of anti-goat IgG
Cy-3 (1:200, Jackson ImmunoResearch) and anti-rabbit-Alexa488 (1:500,
Invitrogen) with a Leica DM 5000B microscope (Leica).
Statistical Analyses
Results are given as means ± SEM. Statistical analyses were performed via
ANOVA and/or Student’s t test.
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